Liquid Biopsy in Paraneoplastic Neurological Syndromes

Recruiting now

Conditions studied: Paraneoplastic Neurological Syndromes

In brief

The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.

Key facts

Study ID

NCT07491328

Run by

Heinrich-Heine University, Duesseldorf

People needed

60

Starts

2023-05-20

Expected to finish

2030-12-30

Last updated by the study team

2026-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies or
• Patients with peripheral tumors without PNS

You may not qualify if…

• Age below 18 years at the time of inclusion.
• Any mental condition impairing the capacity to provide informed consent.
• Presence of contraindications to DLA.

Where it is running

• Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf — Düsseldorf, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.